Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria
Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Based upon the preclinical evidence in models of diabetic nephropathy under conditions
approximating both type I and II diabetes, treatment with alagebrium appears to have
favorable and advantageous effects on the biochemical, structural, pathological and
functional hallmarks of diabetic nephropathy. The renoprotective effects of alagebrium in
preclinical models favor the evaluation of this drug in patients with type I diabetes.